常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.39/-0.47
|
|
企業價值
51.90M
|
| 資產負債 |
|
每股賬面淨值
0.14
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.30
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2025/11/16 08:42 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consistsof nafamostat product candidates and pre-filled syringe product candidates. |

1.25 
